China NMPA Registration of Drugs for Human Use Whitepaper

China NMPA Registration of Drugs for Human Use Whitepaper

China has become one of the world’s most significant pharmaceutical markets, with increasing demand for innovative and generic medicines. However, companies seeking to introduce pharmaceutical products into mainland China must navigate a complex regulatory framework governed by the National Medical Products Administration (NMPA) and associated regulatory bodies.

This whitepaper provides an overview of the regulatory framework for registering drugs for human use in China. It explains the key authorities involved, drug classification systems, approval pathways, and the registration process required for pharmaceutical manufacturers entering the Chinese market.

Why This Topic Matters

China’s pharmaceutical regulatory environment has evolved rapidly in recent years as the country has modernized its drug approval system and aligned more closely with international regulatory standards.

According to the NMPA, China’s Center for Drug Evaluation accepted 16,898 drug registration applications in 2023, representing a 36.6 percent increase compared with 2022 and indicating continued growth in pharmaceutical innovation and development activity.

These developments reflect broader regulatory reforms introduced through legislation such as the Drug Administration Law (DAL) and the Drug Registration Regulation (DRR), as well as China’s participation in the International Council for Harmonisation (ICH). Together, these reforms have reshaped the approval pathways and documentation requirements for pharmaceutical products entering the Chinese market.

For pharmaceutical manufacturers, understanding these regulatory structures and approval pathways is essential for successful market entry and lifecycle compliance.

What You Will Learn in This Whitepaper

This whitepaper explains the regulatory and procedural requirements involved in registering pharmaceutical products in China.

Key topics include:

• The regulatory framework governing pharmaceutical approvals in China
• The roles of the NMPA and other regulatory authorities
• Drug classification systems used in the Chinese regulatory environment
• Approval pathways for innovative, improved, and generic drugs
• The clinical trial and drug registration process
• Requirements for foreign manufacturers and legal agents in China
• Post-approval responsibilities including renewals and change applications.

Regulatory Framework for Drug Approval in China

Drug regulation in China is administered through a multi-layered regulatory structure involving several national authorities.

Key organizations include:

• State Administration for Market Regulation (SAMR) — responsible for overall market supervision and product safety management
• National Medical Products Administration (NMPA) — responsible for supervising drug safety and approving drug registrations
• Center for Drug Evaluation (CDE) — responsible for technical review of drug registration applications
• National Institutes for Food and Drug Control (NIFDC) — responsible for drug testing and quality standard verification
• Center for Food and Drug Inspection (CFDI) — responsible for conducting inspection activities related to drug approval.

China’s pharmaceutical regulatory framework is supported by legislation, regulatory measures, and technical guidelines, including the Chinese Pharmacopoeia (ChP), which defines official quality standards for pharmaceutical products marketed in China.

Drug Classification in China

Before submitting a drug registration application, manufacturers must determine the appropriate classification of their pharmaceutical product.

Drugs in China are generally divided into three primary categories:

Chemical Drugs

Chemical drugs include synthetic pharmaceutical compounds used to prevent or treat diseases. These are typically classified into:

• innovative chemical drugs
• improved chemical drugs
• generic drugs.

Traditional Chinese Medicines (TCM)

Traditional Chinese Medicines are products developed according to the principles of traditional Chinese medicine. Registration categories include:

• innovative TCM products
• improved TCM formulations
• renowned compound TCM preparations.

Biological Products

Biological products are medicines derived from biological sources such as microorganisms or living cells. These may include:

• preventive biological products such as vaccines
• therapeutic biological products such as monoclonal antibodies
• diagnostic reagents managed as biological products.

Correct classification determines the regulatory pathway, documentation requirements, and approval process.

Drug Approval Pathways in China

Manufacturers seeking to market pharmaceutical products in China must obtain approval from the NMPA before the drug can be imported, sold, or used.

Drug registration applications generally fall into several categories:

• Clinical trial applications (CTA)
• Marketing authorization applications (MAA)
• Supplementary applications for post-approval changes
• Re-registration applications.

In addition to the standard review process, China also provides expedited approval pathways designed to accelerate access to important therapies. These include:

• priority review pathways
• breakthrough therapy designation
• conditional approval mechanisms
• special approval for public health emergencies.

These mechanisms may reduce review timelines for drugs addressing urgent medical needs or rare diseases.

Drug Registration Process

Drug registration for foreign pharmaceutical manufacturers must be conducted through a Chinese authorized representative known as the NMPA Legal Agent.

The Legal Agent serves as the regulatory liaison between the Marketing Authorization Holder (MAH) and Chinese regulatory authorities.

Key responsibilities include:

• submitting regulatory documentation and application dossiers
• coordinating communications with regulatory authorities
• supporting regulatory inspections and compliance activities
• assisting with administrative requirements associated with drug registration.

The MAH retains responsibility for the safety, efficacy, and quality of the pharmaceutical product throughout its lifecycle.

Clinical Trials & Marketing Authorization

For innovative or improved drugs that have not yet been marketed globally, clinical trials are typically required before applying for marketing authorization in China.

Possible scenarios include:

• conducting full clinical trials in China
• conducting bridging trials when overseas clinical data is available
• relying on multi-regional clinical trials that include Chinese populations.

Once clinical evaluation is completed, applicants may submit a marketing authorization application to the Center for Drug Evaluation.

Typical steps in the marketing authorization process include:

• preparation and submission of the application dossier
• technical review conducted by the CDE
• drug testing performed by the NIFDC
• inspection activities carried out by the CFDI
• issuance of the marketing authorization certificate by the NMPA.

The full marketing authorization process may take several years depending on the complexity of the product and clinical data requirements.

Post-Approval Lifecycle Management

After receiving marketing authorization, pharmaceutical manufacturers must maintain regulatory compliance throughout the product lifecycle.

Key post-approval obligations include:

• monitoring safety and adverse drug reactions
• managing regulatory changes through change applications
• maintaining compliance with GMP, GCP, and GLP requirements
• submitting renewal applications before marketing authorization expires.

The NMPA marketing authorization certificate is typically valid for five years, after which the Marketing Authorization Holder must apply for re-registration to maintain market authorization.

Who Should Read This Whitepaper

This whitepaper is particularly relevant for:

• Pharmaceutical manufacturers planning to enter the Chinese market
• Regulatory affairs professionals responsible for NMPA submissions
• Drug development teams preparing clinical trial strategies for China
• Compliance and quality assurance teams managing pharmaceutical approvals
• Market-entry teams evaluating regulatory pathways for pharmaceutical products in China.